Moccia ML - Search Results

1

Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology.

Frett B, Carlomagno F, Moccia ML, Brescia A, Federico G, De Falco V, Admire B, Chen Z, Qi W, Santoro M, Li HY. Frett B, et al. Among authors: moccia ml. Angew Chem Int Ed Engl. 2015 Jul 20;54(30):8717-21. doi: 10.1002/anie.201501104. Epub 2015 Jun 30. Angew Chem Int Ed Engl. 2015. PMID: 26126987 Free PMC article.

2

Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

Frett B, Moccia M, Carlomagno F, Santoro M, Li HY. Frett B, et al. Eur J Med Chem. 2014 Oct 30;86:714-23. doi: 10.1016/j.ejmech.2014.09.023. Epub 2014 Sep 8. Eur J Med Chem. 2014. PMID: 25232968 Free PMC article.

3

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.

Moccia M, Liu Q, Guida T, Federico G, Brescia A, Zhao Z, Choi HG, Deng X, Tan L, Wang J, Billaud M, Gray NS, Carlomagno F, Santoro M. Moccia M, et al. PLoS One. 2015 Jun 5;10(6):e0128364. doi: 10.1371/journal.pone.0128364. eCollection 2015. PLoS One. 2015. PMID: 26046350 Free PMC article.

4

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology.

Moccia M, Frett B, Zhang L, Lakkaniga NR, Briggs DC, Chauhan R, Brescia A, Federico G, Yan W, Santoro M, McDonald NQ, Li HY, Carlomagno F. Moccia M, et al. J Med Chem. 2020 May 14;63(9):4506-4516. doi: 10.1021/acs.jmedchem.9b01336. Epub 2020 Apr 28. J Med Chem. 2020. PMID: 32298114 Free PMC article.

5

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues.

Santoro M, Moccia M, Federico G, Carlomagno F. Santoro M, et al. Genes (Basel). 2020 Apr 15;11(4):424. doi: 10.3390/genes11040424. Genes (Basel). 2020. PMID: 32326537 Free PMC article. Review.

6

Discovery of pyrazolo-thieno[3,2-d]pyrimidinylamino-phenyl acetamides as type-II pan-tropomyosin receptor kinase (TRK) inhibitors: Design, synthesis, and biological evaluation.

Yan W, Zhang L, Lv F, Moccia M, Carlomagno F, Landry C, Santoro M, Gosselet F, Frett B, Li HY. Yan W, et al. Eur J Med Chem. 2021 Apr 15;216:113265. doi: 10.1016/j.ejmech.2021.113265. Epub 2021 Feb 9. Eur J Med Chem. 2021. PMID: 33652352

7

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases.

Moccia M, Yang D, Lakkaniga NR, Frett B, McConnell N, Zhang L, Brescia A, Federico G, Zhang L, Salerno P, Santoro M, Li HY, Carlomagno F. Moccia M, et al. Sci Rep. 2021 Aug 9;11(1):16103. doi: 10.1038/s41598-021-95612-4. Sci Rep. 2021. PMID: 34373541 Free PMC article.

8

Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.

Zhang L, Moccia M, Briggs DC, Bharate JB, Lakkaniga NR, Knowles P, Yan W, Tran P, Kharbanda A, Wang X, Leung YK, Frett B, Santoro M, McDonald NQ, Carlomagno F, Li HY. Zhang L, et al. J Med Chem. 2022 Jan 27;65(2):1536-1551. doi: 10.1021/acs.jmedchem.1c01280. J Med Chem. 2022. PMID: 35081714 Free PMC article.

9

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms.

Porcelli T, Moccia M, De Stefano MA, Ambrosio R, Capoluongo E, Santoro M, Hadoux J, Schlumberger M, Carlomagno F, Salvatore D. Porcelli T, et al. JCO Precis Oncol. 2023 Aug;7:e2300052. doi: 10.1200/PO.23.00052. JCO Precis Oncol. 2023. PMID: 37535881 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters